Codiak presented data at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy demonstrating the feasibility to manufacture therapeutic engineered exosomes from site specific integration
Codiak presented data at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy demonstrating that exoASOs against C/EBPβ represent a first-in-class strategy to reprogram tumor-associated
myeloid cells in a highly selective manner.
Codiak presented data at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy demonstrating that the engEx platform is effective for the precision engineering of multifunctional exosomes.
Codiak presented data at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy demonstrating the potential of engineered exosomes incorporating an antisense oligonucleotide (ASO) to selectively reprogram tumor-associated macrophages and generate potent anti-tumor activity.
Codiak presented data at The Society for Immunotherapy of Cancer (SITC) supporting that exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12.
Codiak presented data at The Society for Immunotherapy of Cancer (SITC) demonstrating that exoSTING shows unique pharmacodynamic effects and tumor antigen-specific systemic immune responses compared to free STING agonist.
Codiak presented data supporting the identification of a novel and selective scaffold protein, PTGFRN, as part of its engEX exosome platform at the Annual Meeting of the International Society for Extracellular Vesicles (ISEV).
Codiak presented data supporting the potential of its engEX™ Platform and its proprietary PTGFRN protein scaffold at the 2019 American Association for Cancer Research (AACR) Annual Meeting.
Codiak presented preclinical data in support of its engEx Platform for engineering exosomes at the Keystone Symposium on Cancer Immunotherapy.